Health
Triggering tumor antiviral immune response in triple negative breast cancer – EurekAlert
Researchers at Baylor College of Medicine have discovered how therapeutics targeting RNA splicing can activate antiviral immune pathways in triple negative breast…
HOUSTON – (Jan. 14, 2021) – Researchers at Baylor College of Medicine have discovered how therapeutics targeting RNA splicing can activate antiviral immune pathways in triple negative breast cancers (TNBC) to trigger tumor cell death and signal the body’s immune response. A new study published in Cell shows that endogenous mis-spliced RNA in tumor cells mimics an RNA virus, leading tumor cells to self-destruct as if fighting an infection. Researchers suggest this mechanism could open new avenues…
-
General21 hours agoGeelong Cats AFL star Bailey Smith details mental health battle during All-Australian speech
-
Noosa News12 hours agoBrisbane nation’s third-youngest capital; Leaders condemn anti-immigration rally
-
Noosa News20 hours agoQld nurses poised to strike deal with Crisafulli government
-
General17 hours agoUS CDC boss Susan Monarez refuses to quit, defying Trump’s White House